SEARCH

SEARCH BY CITATION

References

  • 1
    Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:15801583.
  • 2
    Mauldin GN, Matus RE, Patnaik AK, et al. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med 1988;2:6065.
  • 3
    Rasheed ZA, Rubin EH. Anthracyclines. In: DeVita VT, Lawrence TS, Rosenberg SA, ed. Cancer: Principles & Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:441443.
  • 4
    ECVIM-CA. Preventing occupational and environmental exposure to cytotoxic drugs in veterinary medicine, 2nd ed. Available at: http://www.ecvim-ca.org/guidelines. Accessed July 2007.
  • 5
    Selting KA, Ogilvie GK, Gustafson DL, et al. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res 2006;67:145151.
  • 6
    Barpe DR, Rosa DD, Froehlich PE. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Europ J Pharm Sci 2010;41:458463.
  • 7
    Information P. Adriamycin (DOXOrubicin HCL). Beford, OH: Bedford Laboratories; 2010.
  • 8
    Theon AP, Wilson WD, Magdesian KG, et al. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004). J Am Vet Med Assoc 2007;230:15061513.
  • 9
    Owen LN. TNM Classification Of Tumours in Domestic Animals, 1st ed. Geneva: World Health Organization; 1980:4647.
  • 10
    Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143151.
  • 11
    Jung SH, Lee T, Kim K, et al. Admissible two-stage designs for phase II cancer clinical trials. Stat Med 2004;23:561569.
  • 12
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228247.
  • 13
    Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Can Res 2010;16:48324842.
  • 14
    Wagner J. Noncompartmental and system analysis. In: Wagner JG, ed. Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA: Technomic Publishing Company Inc; 1993:8399.
  • 15
    Kaplan EL, Meier P. Kaplan Meier Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457481.
  • 16
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Can Inst 2000;92:205216.
  • 17
    Chun R, Garrett LG, Vail DM. Cancer chemotherapy. In: Withrow S, Vail D, eds. Small Animal Clinical Oncology, 4th ed. St. Louis, MO: Saunders Elsevier; 2007:163192.
  • 18
    Susaneck SJ. Doxorubicin therapy in the dog. J Am Vet Med Assoc 1983;182:7072.
  • 19
    Doroshow JH. Anthracyclines and anthracenediones. In: Chabner B, Longo D, eds. Cancer Chemotherapy & Biotherapy: Principles & Practices, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:415450.
  • 20
    Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Phys Endocrinol Metab 2001;281:E586E591.
  • 21
    deVita VT, Chu E. Principles of medical oncology. In: VT D, TS L, SA R, ed. Cancer: Principles & Practice of Oncology, 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:337342.
  • 22
    Doroshow JH. Anthracyclines and anthracenediones. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy & Biotherapy: Principles & Practices. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:415450.
  • 23
    Creasey WA, McIntosh LS, Brescia T, et al. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Can Res 1976;36:216221.
  • 24
    Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Can Surv 1993;17:219252.
  • 25
    Knobloch A, Mohring SA, Eberle N, et al. Cytotoxic drug residues in urine of dogs receiving anticancer chemotherapy. J Vet Intern Med 2010;24:384390.
  • 26
    Le Bot MA, Riche C, Guedes Y, et al. Study of doxorubicin photodegradation in plasma, urine and cell culture medium by HPLC. Biomed Chromato 1988;2:242244.